Strictly confidential How to achieve sustainability in rapidly changing environment? Pavle Marjanović, Country Manager for Actavis Republic of Serbia and.

Slides:



Advertisements
Similar presentations
1 Policy options to address access to chronic disease medicines Dr. Richard Laing Ms. Alexandra Cameron Department of Essential Medicines and Pharmaceutical.
Advertisements

Pricing and paying for medicines Ad Antonisse AstraZeneca BV April 2005.
What can Actavis contribute for the sustainability in the health care system?
Efficiency, Ethics and Cost in Pharmaceutical Research and Manufacturing Matthew Wirtala Spring 2006.
SEBs – A Public Payer Perspective
The Medical Innovation Prize Fund S.2210, 110 th U.S. Congress David Reynolds, DrPH Senior Health Policy Advisor Senator Bernie Sanders
Patent linkage and the TPP Commercial considerations relevant to TPP 1 Geraldine Storton Hospira Pty Ltd.
Lecture 9 Tuesday, October 2 Healthcare and the Market.
Innovations: Using a Clinical Pharmacist as a Vehicle for Successful P4P Outcomes Lisa Meland, B.S., PharmD. Helen Pervanas, R.Ph. WellPoint-WellPoint.
The Global Generic Medications Market
International Experience in Pharmaceutical Services for Promoting Access to Medicines: Canada, Cuba, England, Mexico International Seminar on the Challenges.
PAHO/WHO Seminar Brasilia October 2002 PAHO/WHO INTERNATIONAL SEMINAR ON CHALLENGES FOR COMPREHENSIVE PHARMACEUTICAL SERVICES BRASILIA, OCTOBER 2002 Experience.
Pharmaceutical Services Unit Essential Medicines Management
SUCCESS FACTORS IN THE PHARMACEUTICAL MARKETPLACE
Universal Health-Care Will this Policy Benefit the United States? By Matthew Lokant.
Drug Pricing in Canada Victoria Brown, Anureet Sohi, Lisa Weger SPHA 511.
Pharmaceuticals before and after TRIPS Sudip Chaudhuri Professor of Economics Indian Institute of Management Calcutta BRICS Workshop, Aalborg February,
Medicines & Related Substances Amendment Bill: Protecting the Nation’s Health “The State must take reasonable legislative and other measures, within its.
The Role of TNCs and AIDS drugs – “Lives before profits”? L.O.s 1.To define the terms: TNC, Generic, “Big Pharma”, ARVs, HAART, Tiered Pricing. 2.To describe.
Measles Partnership Meeting Yalda Momeni September 23 rd - WDC.
3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.
Improving access to generic & biosimilar medicines in Bulgaria and in the EU 1 Adrian van den Hoven Director General EGA – European Generic medicines Associations.
CH 1. Factors accounting for the growth of importance in the health sector  Global health and longevity gains  Expansion of health sector throughout.
European Commission Dialogue-Innovation-Future An experience of the Pharmaceutical Forum Dr Stefaan Van der Spiegel, MD Competitiveness in the Pharmaceuticals.
LIST OF DRUGS COVERED BY HEALTH INSURANCE FUND OF THE REPUBLIC OF MACEDONIA Ms. Maja Parnardzieva – Zmejkova, MSc, CEO October 2011.
SWITCHING OF MEDICINES 19 June SWITCH Reclassification of legal status of a medicine Typically one with many years of experience of safe use From.
The competition between innovative and generic pharmaceutical companies intensified in the last decades. The models created by innovative pharmaceutical.
Trade-related policies and access to medicines ICTSD Consultation on trade policy coherence and access to medicines Geneva November 7 th 2006,
Pharmaceutical benefit management under health insurance – common issues in emerging economies Zagreb, January 19, 2010 Andreas Seiter World Bank.
The Pharmaceutical Industry in Turkey
1 Public Procurement of Innovations a driver for future health in Europe - Stockholm, 13 October 2009 Public Procurement Directives supporting innovation.
3rd National Conference on medicines policy, Bratislava December 2006 Medicines Policy and equity in health How can generic drug producers contribute?
Specialty Drug Benefit Management: Raymond Rupert MD. MBA. Rupert Case Management Inc.
MSF Access Campaign Started in 1999 Rooted in field experience Three Pillars: –Overcoming Barriers –Research and Development for Drugs for Neglected Diseases.
Patents and Medicines: How the system has discouraged innovation and reduced patient access to benefits of knowledge GREG PERRY Director General, EGA World.
Competitiveness of the European-based Pharmaceutical Industry Prospective of a New Member State Imre Hollo Deputy Secretary of State, MOH Hungary.
AIFA European Conference on Clinical Research for Decision Making Sergio Dompé - Farmindustria Rome, March 30th, 2007 Access to market by new medicines.
The Innovative Medicines Initiative A winning case for Joint Technology Initiative Status.
10/22/2015 AER Social Politics & Public Health Committee 2, Katowice ( Slaskie, PL ) A REVIEW OF THE HEALTH SYSTEM IN ROMANIA
Title text here Consumer Perspective on Containing Drug Costs Leigh Purvis, Director, Health Services Research.
1/7 Are Patients Today Sufficiently Informed? Right and Ethics 10 October 2007.
Entry and Regulation – Evidence from Health Care Professions Prof. Frank Verboven Presentation at DG-Competition 13 December 2006 “The Economic case for.
An Alternative to Pharmaceutical Patents Christian Engström Vice Chairman, The Swedish Pirate Party.
4. Access to medication & healthcare Learning objectives: - to identify the why many people cannot access medication - to understand how NGOs and the UN.
Project no_File reference IMS Health Baltic September 2005 Baltic pharma market 1999 – 2004 Developments, changes and possible future trends.
The Pharmaceutical Composition Methodology described in this presentation has been developed to improve controlled drug delivery through site specific.
Philippe Duneton11 February 2009 Deputy Executive Secretary 5th Consultative Stakeholder Meeting UN Prequalification of Diagnostics, Medicines & Vaccines.
Ellen ‘t Hoen Médecins sans Frontières
© Safeguarding public health Can Europe grow its Medtech industry and lead the world on medical device regulation? John Wilkinson 20 th September 2012.
Patents, Prizes, AMCs and CAMCs Aidan Hollis University of Calgary October 2007.
“Supporting the Industry through Communication” The pharmaceutical industry is committed to the research, development, quality manufacturing and logistics.
The Role of New Markets Advisors in Healthcare Case Study in Pharma.
Rethinking Health Innovation from the South WORKSHOP South Africa/ Cape town December 13 – 15 /2010.
Health Technology Assessment for Pharmaceuticals and New Medical Technologies - Where are we now? The industry perspective Jenny Hughes, Director, Vaccines.
Evolving Practices in the Assessment of Medical Devices An Industry Perspective Adrian Griffin | April 2016.
Aarkstore - Metastatic Ovarian Cancer- Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 Category : Pharmaceuticals and Healthcare.
Health Policy Issues An Economic Perspective Copyright © 2015 Foundation of the American College of Healthcare Executives. Not for sale.
GB590 Corporate Social Responsibility Prof. Ray Kalinski By Willette Marchany Rivera December 13, 2010.
Role of innovation in state of the art healthcare delivery in Russia 27 October 2015, USRBC Annual Meeting.
The pharmaceutical market in Europe
Quality patients value sustainability partnership Value of generic medicines.
Research & development
Health Technology Assessment
HEALTH ECONOMICS BASICS
Cooperation for Better Regulation
Finland, a Global Testbed for Personalized Cancer Research?
Entry and Regulation – Evidence from Health Care Professions
Croatia, Zagreb, September 4, 2018 Ljiljana Sović Brkičić
Croatia, Zagreb, June 29, 2018 Ljiljana Sović Brkičić
Expert Speak: How Pharma Companies Can Grow Their Business?
Presentation transcript:

Strictly confidential How to achieve sustainability in rapidly changing environment? Pavle Marjanović, Country Manager for Actavis Republic of Serbia and Republic of Montenegro October 5 th, 2011

Main changes in the pharmaceutical industry Limited number of new molecules in R&D pipelines (except some “me too” molecules)=> lack of fundamental innovation/patent expiry Aging population, higher demand for the therapy Less money in sick fund(s) Reference pricing, tenders leading to constant price erosion (example paclitaxel USA) Liquidity issues Big Pharma enters Gx segment Prescription limitations Focus on medical compliance, prevention Focus on legal compliance and ethics 2

Generic industry ensures healthcare sustainability Gx medicines enhancing competition – SAVINGS Drugs are becoming affordable especially for chronic diseases Gx medicines could provide innovation – new formulations, methods of delivery 3

Gx entry should be supported by relevant authorities Time limited “exclusivity” for the first Gx entry – SAVINGS! Value of products going off patent expected to increase from 2011 – SAVINGS! Evaluating each segment of drug approval seeking possible “fast tracks” for Gx 4

Serbia vs. relevant European markets 5

Gx entry brings sustainability to healthcare system Lowering prices could enable broader number of patients treated Statins consumption among lowest in Europe Reinforcing the position of “family doctor” making decisions for the treatment of the major chronic diseases Old drugs (from ‘60, ’70) could be replaced with new generation Gx drugs at the same price Typical/Atypical antipsychotics – 50% of patients treated with typical antipsychotics Antidepressants - 40% of patients treated with older antidepressants Antidiabetics Sartans Peculiarity of the Serbian market – Gx industry brings innovative molecules to the market at affordable prices OTC status liberalization (ranitidine, loratadine etc) Savings could be used for extending generic therapeutic categories 6

Actavis role in bringing sustainability to healthcare system Meeting healthcare needs More affordable prices Modern therapies More patients treated Overall cost saving …in partnership with relevant authorities and through transparent dialogue! 7

This is not the best way to calculate healthcare budget figures 8